Clinical research progress of targeted therapy combined with immunotherapy for advanced cholangiocarcinoma.

Cholangiocarcinoma (CCA) is a common and highly malignant form of cancer that has shown high rates of morbidity and mortality in recent years. The prognosis for cholangiocarcinoma is generally poor due to its aggressive nature and high recurrence rate. Most patients are diagnosed in the middle or late stages of the disease, making surgical treatment challenging. As a result, there is a pressing need to improve the treatment of advanced cholangiocarcinoma. The advancement of tumor genetics has allowed for more precise and targeted treatment approaches. Targeted molecular therapy has shown promise in cholangiocarcinoma treatment, and the study of immunotherapy has provided hope for patients who are not eligible for surgery or have a poor response to chemotherapy. However, the effectiveness of single targeted therapy or immunotherapy is limited. Therefore, the combination of targeted therapy and immunotherapy represents a significant breakthrough and challenge. Recent research on the combination of targeted therapy and immunotherapy in cholangiocarcinoma has yielded promising results, surpassing the outcomes of single therapy or chemotherapy. This has sparked intense interest in further investigating this combined approach. In this article, we aim to review the development and research findings of targeted therapy combined with immunotherapy, providing new insights for the selection of combined therapy and future clinical research in cholangiocarcinoma.